FREE Account Opening + No Clearing Fees

Dr. Lal PathLabs Limited IPO Review (Apply)

Review By Dilip Davda on December 2, 2015

After a gap of five week’s calmness, primary market is once again gearing for some activities with a main board IPO from Dr Lal Pathlabs Ltd, which is coming out totally with its secondary offer for mobilization of around Rs. 625 crore. Details of the IPO are as under:

Dr Lal Pathlabs Ltd (LPL) has been in the business of consumer health since 1949 and has established its niche brand in the field of diagnosis services with over 20 % CAGR for past three years. LPL is a provider of diagnostic and related healthcare tests and services in India. Through its integrated, nationwide network, it offers patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. Its customers include individual patients, hospitals and other healthcare providers and corporate customers. In the Fiscal Year 2015, LPL collected and processed approximately 21.8 million samples from approximately 9.9 million patients.

According to management, it believes that the increasing prescription of diagnostic tests and services by healthcare providers in India, combined with the growing focus on early detection and prevention of chronic and lifestyle diseases, such as diabetes, hypertension, heart disease and cancer, creates a significant market opportunities.

Now to unlock the stakeholders value the company is coming out with a maiden IPO for listing purpose by way of secondary offer and has planned offer for sale of 11600000 equity share of Rs. 10 each by existing shareholders in a price band of Rs. 540-550 by way of book building route. Mini mum application is to be made for 20 shares and in multiples thereon, thereafter. IPO opens for subscription on 08.12.15 and will close on 10.12.15. Anchor bids will open on 07.12.15. The company is offering Rs. 15 special discount to retail investors as a gesture of goodwill. BRLM to this offer are Kotak Mahindra Capital Co. Ltd and Citigroup Global Markets India Pvt Ltd. Link Intime India Pvt Ltd is the registrar to this issue. Post allotment, shares will be listed on BSE/NSE. This offer constitutes 14.04% equity dilution of the post offer paid up equity.

On performance front, (on a consolidated basis) it has posted an average EPS of Rs. 14.62 (basic) and Rs. 10.12 (diluted) basis and return on net worth of around 31% for last three fiscals. For first half of current year it has reported net profit of Rs. 37.47 crore (after deducting special item of Rs. 16.63 crore) on a turnover of Rs. 407.71 crore. It has issued bonus shares in the ratio of 3 for 1 in September 2003 and 15 for 1 in September 2013. Last ESOPs done by the company during 2015 so far was at a price of Rs. 110.80 per share.   If we annualized this and attribute on the existing equity capital of Rs. 82.65 crore (as no fresh equity is being issued), the asking price is at a P/E of 48 plus and at a P/BV of 8 plus makes it an expensive offer. Average cost of acquisition by the promoters is below Re. 1 per share.

Conclusion / Investment Strategy

As this is the first company under consumer healthcare diagnosis services sector having established brand and has no listed peers to compare with, it may enjoy the benefit of first mover of the sector and hence may attract fancy of investors. Although it being an expensive offer, moderate investment for short to medium term may be considered.

Reviewer recommends Subscribing to the issue.

Review By Dilip Davda on December 2, 2015

Review Author

DISCLAIMER: No financial information whatsoever published anywhere here should be construed as an offer to buy or sell securities, or as advice to do so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions. Readers must consult a qualified financial advisor before making any actual investment decisions, based on the information published here. My reviews do not cover GMP market and operators game plans. Any reader taking decisions based on any information published here does so entirely at their own risk. Investors should bear in mind that any investment in stock markets is subject to unpredictable market-related risks. The above information is based on RHP and other documents available as of date coupled with market perception. The author has no plans to invest in this offer.

About Dilip Davda

Dilip Davda, a freelance journalist

Dilip Davda is veteran journalist associated with stock market since 1978. He is contributing to print and electronic media on stock markets/insurance/finance since 1985.

Dilip Davda is a leading reviewer of public issues and NCDs in the primary stock market in India. The knowledge he gained over 3 decades while working in the stock market and a strong relationship with popular lead managers makes his reviews unique. His detail fundamental and financial analysis of companies coming up with IPO helps investors in the primary stock market. Dilip Davda has a special interest in analyzing the SME companies and writing reviews about their public issues. His reviews are regularly published online and in news papers.

(Dilip Davda -SEBI registered Research Analyst-Mumbai,

Registration no. INH000003127 (Perpetual)

Email id: ).

Dr Lal PathLabs IPO FAQs

  1. 1. Why Dr Lal PathLabs IPO?

    The initial public offer (IPO) of Dr. Lal PathLabs Limited offers an early investment opportunity in Dr. Lal PathLabs Limited. A stock market investor can buy Dr Lal PathLabs IPO shares by applying in IPO before Dr. Lal PathLabs Limited shares get listed at the stock exchanges. An investor could invest in Dr Lal PathLabs IPO for short term listing gain or a long term.

  2. 2. How is Dr Lal PathLabs IPO?

    Read the Dr Lal PathLabs IPO recommendations by the leading analyst and leading stock brokers.

  3. 3. Dr Lal PathLabs IPO what should investors do?

    Dr Lal PathLabs IPO offers an opportunity to buy IPO shares before they get listed at the stock exchanges. Read the Dr Lal PathLabs IPO Notes, Analysis and Recommendations by leading stock brokerage firms and experts in the above answer.

  4. 4. Is Dr Lal PathLabs IPO good?

    Our recommendation for Dr Lal PathLabs IPO is to subscribe.

  5. 5. Is Dr Lal PathLabs IPO worth Investing?

    As per the analysis by our lead analyst Mr. Dilip Davda, we suggest you to subscribe to the Dr Lal PathLabs IPO.

  6. 6. When will Dr Lal PathLabs IPO allotment status?

    The Dr Lal PathLabs IPO allotment status will be available on or around [.]. The allotted shares will be credited in demat account by [.]. Visit Dr Lal PathLabs IPO allotment status to check.

  7. 7. When will Dr Lal PathLabs IPO list?

    The Dr Lal PathLabs IPO will list on Wednesday, December 23, 2015, at BSE, NSE.